Loading...
SeqLL Inc.
SQL•NASDAQ
Healthcare
Medical - Diagnostics & Research
$6.60
$-0.16(-2.38%)

Financial performance has remained strong, with revenue growing from $78659.00 in Q4 2022 to $0.00 in Q3 2023. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$1.29M in Q3 2023, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.25M. Net income rose to -$1.27M, keeping EPS at -$3.33. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan